A Study of RO5045337 in Patients With Solid Tumors

NCT01164033 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: RO5045337

Sponsor

Hoffmann-La Roche